Advertisement

Pathology & Oncology Research

, Volume 7, Issue 4, pp 260–266 | Cite as

Expression of a decorin-like molecule in human melanoma

  • Andrea Ladányi
  • Mónika Gallai
  • Sándor Paku
  • Julianna O. Nagy
  • József Dudás
  • József Tímár
  • Ilona Kovalszky
Article

Abstract

Decorin, a member of the family of small leucin-rich proteoglycans, has originally been described as a secreted proteoglycan component of the connective tissues, and has been implicated in the negative regulation of cell proliferation directly or via interactions with TGF-β. It was reported to be generally absent from tumor cells. Here we show that human melanoma cell lines express a decorin-like molecule. We detected decorin mRNA by RT-PCR in 7 out 7 human melanoma lines characterized by various metastatic potential. Using polyclonal antiserum against the core protein of decorin, the typical 80–120 kD glycanated form as well as a high molecular weight aberrant version (200–210 kD) of decorin were demonstrated by Western blot technique in the culture supernatants as well as in lysates of human melanoma cells. Finally, decorin epitope was also demonstrated immunohistochemically in human melanoma xenografts, as well as in tumor cells of surgically resected melanomas but not in melanocytes of nevi. The expression of this aberrant decorin did not inhibit thein vitro orin vivo growth of human melanoma cells, and it was independent of their metastatic potential. Human melanoma cell lines expressing aberrant decorin retained sensitivity to the antiproliferative and gelatinase-stimulatory effects of exogenous TGF-β.

Keywords

decorin human melanoma mRNA protein TGF-beta 

Abbreviations

CS

chondroitin sulfate

PG

proteoglycan

TGF

transforming growth factor

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.2
    Krusius T, Ruoslahti E: Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc Natl Acad Sci USA 83:7683–7687, 1986.PubMedCrossRefGoogle Scholar
  2. 2.2
    Iozzo RV: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32:141–174, 1997.PubMedCrossRefGoogle Scholar
  3. 3.2
    Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346:281–284, 1990.PubMedCrossRefGoogle Scholar
  4. 4.2
    Border WA, Noble NA, Yamamoto T, et al: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360361-364, 1992.Google Scholar
  5. 5.2
    Takeuchi Y, Kodama Y, Matsumoto T: Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J Biol Chem 269:32634–32638, 1994.PubMedGoogle Scholar
  6. 6.2
    Hausser H, Gröning A, Hasilik A, et al.: Selective inactivity of TGF-β/decorin complexes. FEBS Lett 353:243–245, 1994.PubMedCrossRefGoogle Scholar
  7. 7.2
    Coppock DL, Kopman C, Scandalis S, et al: Preferential gene expression in quiescent human lung fibroblasts. Cell Growth Differ 4:483–493, 1993.PubMedGoogle Scholar
  8. 8.2
    Mauviel A, Santra M, Chen YQ, et al: Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-α. J Biol Chem 270:11692–11700, 1995.PubMedCrossRefGoogle Scholar
  9. 9.2
    Santra M, Mann DM, Mercer EW, et al: Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100:149–157, 1997.PubMedCrossRefGoogle Scholar
  10. 10.2
    Yamaguchi Y, Ruoslahti E: Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336:244–246, 1988.PubMedCrossRefGoogle Scholar
  11. 11.2
    De Luca A, Santra M, Baldi A, et al: Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271:18961–18965, 1996.PubMedCrossRefGoogle Scholar
  12. 12.2
    Adany R, Heimer R, Caterson B, et al.: Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 265:11389–11396, 1990.PubMedGoogle Scholar
  13. 13.2
    Pluschke G, Vanek M, Evans A, et al: Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710–9715, 1996.PubMedCrossRefGoogle Scholar
  14. 14.2
    Iida J, Meijne AML, Knutson JR, et al: Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 7:155–162, 1996.PubMedCrossRefGoogle Scholar
  15. 15.2
    Timár J, Ladányi A, Lapis K, et al: Differential expression of proteoglycans on the surface of human melanoma cells characterized by altered experimental metastatic potential. Am J Pathol 141:467–474, 1992.PubMedGoogle Scholar
  16. 16.2
    Caux F, Timar J, Lapis K, Moczar M: Proteochondroitin sulphate in human melanoma cell cultures. Biochem Soc Transact 18:293–294, 1990.Google Scholar
  17. 17.2
    Tímár J, Jeney A, Kovalszky I, Kopper L: Role of proteoglycans in tumor progression. Pathol Oncol Res 1:85–93, 1995.PubMedCrossRefGoogle Scholar
  18. 18.2
    Ladányi A, Tímár J, Paku S, et al: Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461, 1990.PubMedCrossRefGoogle Scholar
  19. 19.2
    Ladányi A, Tímár J, Bocsi J, et al: Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res 5:83–86, 1995.PubMedCrossRefGoogle Scholar
  20. 20.2
    Ladányi A, O. Nagy J, Jeney A, et al: Cytokine sensitivity of metastatic human melanoma cell lines - simultaneous inhibition of proliferation and enhancement of gelatinase activity. Pathol Oncol Res 4:108–114, 1998.PubMedCrossRefGoogle Scholar
  21. 21.2
    Vogel KG, Ördög A, Pogány G, et al: Proteoglycans in the compressed region of human tibialis posterior tendon and in ligaments. J Orthop Res 11:68–77, 1984.CrossRefGoogle Scholar
  22. 22.2
    Mueller BM, Romerdahl CA, Trent JM, et al: Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 51:2193–2198, 1991.PubMedGoogle Scholar
  23. 23.2
    Bani MR, Rak J, Adachi D, et al: Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 56:3075–3086, 1996.PubMedGoogle Scholar
  24. 24.2
    Tímár J, Kovalszky I, Paku S, et al.: Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern. J Cancer Res Clin Oncol 115:554–557, 1989.PubMedCrossRefGoogle Scholar
  25. 25.2
    Voss B, Glössl J, Cully Z, Kresse H: Immunocytochemical investigation on the distribution of small chondroitin sulfatedermatan sulfate proteoglycan in the human. J Histochem Cytochem 34:1013–1019, 1986.PubMedGoogle Scholar
  26. 26.2
    Imai K, Hiramatsu A, Fukushima D, et al: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-1 release. Biochem J 322:809–814, 1997.PubMedGoogle Scholar
  27. 27.2
    Danielson KG, Fazzio A, Cohen I, et al: The human decorin gene: intron-exon organization, discovery of two alternatively spliced exons in the 5′ untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15:146–160, 1993.PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2001

Authors and Affiliations

  • Andrea Ladányi
    • 1
  • Mónika Gallai
    • 2
  • Sándor Paku
    • 3
  • Julianna O. Nagy
    • 4
  • József Dudás
    • 4
  • József Tímár
    • 1
    • 4
  • Ilona Kovalszky
    • 4
  1. 1.Department of Tumor ProgressionNational Institute of OncologyBudapestHungary
  2. 2.Department of Molecular PathologyNational Institute of OncologyBudapest
  3. 3.Department of Molecular PathologyJoint Organization of the Hungarian Academy of Sciences and Semmelweis UniversityHungary
  4. 4.1st Institute of Pathology and Experimental Cancer ResearchSemmelweis UniversityBudapestHungary

Personalised recommendations